StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd (TEVA) stock

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30127% above fair value
$42.23−0.39 (-0.92%)

Close on Nov 18, 2026Market cap $49.21BP/E 70.4Yield –

Earnings

Teva Pharmaceutical Industries's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Jan 11, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$4.40B
-2.3% on a year earlier
non-GAAP diluted earnings per share, Q3 FY2026
$0.86
$0.78 a year earlier
Latest guidance
Issued
Nov 3, 2026 · 7 items

Quarterly results

Revenue and earnings per share from each of Teva Pharmaceutical Industries's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Jan 11, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 3, 2026before the open$4.40B-2.3%$0.20$0.86Release
Q2 FY2026ended Jun 30, 2026Jul 29, 2026before the open$4.14B-0.8%-$0.49$0.02Release
Q1 FY2026ended Mar 31, 2026Apr 29, 2026before the open$3.98B+2.1%$0.31$0.53Release
Q4 FY2025ended Dec 31, 2025Jan 12, 2026before the open––––Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025before the open$4.50B+3.9%$0.37$0.78Release
Q2 FY2025ended Jun 30, 2025Jul 30, 2025before the open$4.18B+0.3%$0.24$0.66Release
Q1 FY2025ended Mar 31, 2025May 7, 2025before the open$3.90B+2.1%$0.18$0.52Release
Q4 FY2024ended Dec 31, 2024Jan 29, 2025before the open$4.20B-5.8%-$0.19$0.71Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024before the open$4.33B+12.5%-$0.39$0.69Release
Q2 FY2024ended Jun 30, 2024Jul 31, 2024before the open$4.16B+7.4%-$0.75$0.61Release
Q1 FY2024ended Mar 31, 2024May 8, 2024before the open$3.82B+3.2%-$0.12$0.48Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Teva Pharmaceutical Industries's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenuesFY2026$16.70B – $17.00B–NewNov 3, 2026
RevenuesFY2026$16.50B – $16.85B$16.40B – $16.80BRaisedJul 29, 2026
Non-GAAP operating incomenon-GAAPFY2026$3.80B – $3.90B–NewNov 3, 2026
Non-GAAP operating incomenon-GAAPFY2026$3.80B – $4.00B$3.80B – $4.00BReaffirmedJul 29, 2026
Adjusted EBITDAnon-GAAPFY2026$4.23B – $4.43B–NewNov 3, 2026
Adjusted EBITDAnon-GAAPFY2026$4.23B – $4.53B$4.23B – $4.53BReaffirmedJul 29, 2026
Non-GAAP diluted EPSnon-GAAPFY2026$1.92 – $2.11–NewNov 3, 2026
Non-GAAP diluted EPSnon-GAAPFY2026$1.91 – $2.11$1.91 – $2.11ReaffirmedJul 29, 2026
Free cash flownon-GAAPFY2026$2.10B – $2.40B–NewNov 3, 2026
Free cash flowFY2026$2.00B – $2.40B–NewJul 29, 2026
Free cash flownon-GAAPFY2026$2.00B – $2.40B–NewApr 29, 2026
CAPEXFY2026$500.00M–NewNov 3, 2026
CAPEXFY2026$500.00M–NewJul 29, 2026
annual non-GAAP tax ratenon-GAAPFY202620% – 23%–NewJul 29, 2026
Finance Expenses*FY2026$800.00M–NewJul 29, 2026
non-GAAP tax ratenon-GAAPFY202620% – 23%–NewNov 3, 2026
non-GAAP operating income marginnon-GAAPFY202730%–NewApr 29, 2026
operating profit marginFY202730%–NewJul 30, 2025
operating profit marginnon-GAAPFY202730%–NewMay 7, 2025

Guidance history

Every forecast Teva Pharmaceutical Industries put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 3, 2026CAPEXFY2026$500.00MNew
Nov 3, 2026Adjusted EBITDAFY2026$4.23B – $4.43BNew
Nov 3, 2026Non-GAAP diluted EPSFY2026$1.92 – $2.11New
Nov 3, 2026Free cash flowFY2026$2.10B – $2.40BNew
Nov 3, 2026Non-GAAP operating incomeFY2026$3.80B – $3.90BNew
Nov 3, 2026non-GAAP tax rateFY202620% – 23%New
Nov 3, 2026RevenuesFY2026$16.70B – $17.00BNew
Jul 29, 2026CAPEXFY2026$500.00MNew
Jul 29, 2026Adjusted EBITDAFY2026$4.23B – $4.53BReaffirmed
Jul 29, 2026Non-GAAP diluted EPSFY2026$1.91 – $2.11Reaffirmed
Jul 29, 2026Free cash flowFY2026$2.00B – $2.40BNew
Jul 29, 2026Non-GAAP operating incomeFY2026$3.80B – $4.00BReaffirmed
Jul 29, 2026annual non-GAAP tax rateFY202620% – 23%New
Jul 29, 2026Finance Expenses*FY2026$800.00MNew
Jul 29, 2026RevenuesFY2026$16.50B – $16.85BRaised
Apr 29, 2026Adjusted EBITDAFY2026$4.23B – $4.53BNew
Apr 29, 2026Non-GAAP diluted EPSFY2026$1.91 – $2.11New
Apr 29, 2026Free cash flowFY2026$2.00B – $2.40BNew
Apr 29, 2026Non-GAAP operating incomeFY2026$3.80B – $4.00BNew
Apr 29, 2026non-GAAP operating income marginFY202730%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Teva Pharmaceutical Industries filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. News
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Update
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?